Menu
Home
About Us
About Noxopharm
Board of Directors
Management Team
Our Science
About Veyonda
Publications
Pipeline & Clinical Programs
Investors
Share Price
ASX Announcements
Latest News
Nox Insights
Media
CEO NoxoBlog
Newsletters
Presentations & Interviews
Annual Reports
Financial Reports
Quarterly Reports
Analyst Reports
Corporate Governance
Company Constitution
Privacy Policy
Investor FAQs
Overseas Investors / Glossary
Contact Us
Contact Us
Working at Noxopharm
Email Alerts
NOX:
Market Cap:
Price Delay ~20min
Investors
Home
>
Investors
>
Analyst Reports
Share Price
ASX Announcements
Latest News
Nox Insights
Media
CEO NoxoBlog
Newsletters
Presentations & Interviews
Annual Reports
Financial Reports
Quarterly Reports
Analyst Reports
Corporate Governance
Company Constitution
Privacy Policy
Investor FAQs
Overseas Investors / Glossary
Analyst Reports
5-Sep-2018
EverBlu Capital Research Report: A Closer Look at Nyrada - a Noxopharm subsidiary company.
12-Jul-2018
Noxopharm Research Report prepared by EverBlu Capital Research July 2018
27-Jul-2017
NOX Research Report prepared by APP Securities
25-May-2017
Independent Investment Research Report May 2017
16-Nov-2016
Independent Investment Research Report November 2016
19-Sep-2016
APP Securities Company Research Report September 2016
